Extended Abstracts
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW
R.-D. Hofheinz, C. Dittrich, M.A. Jakupec, A. Drescher, U. Jaehde, M. Gneist, N. Graf v. Keyserlingk, B.K. Keppler and A. Hochhaus
Price
42.00 $
Volume 43 p. 590 - 591
Abstract
R.-D. Hofheinz, C. Dittrich, M.A. Jakupec, A. Drescher, U. Jaehde, M. Gneist, N. Graf v. Keyserlingk, B.K. Keppler and A. Hochhaus
Extended Abstracts
Reactivity of novel albumin-binding platinum complexes
D. Garmann, A. Warnecke, F. Kratz and U. Jaehde
Price
42.00 $
Volume 42 p. 646 - 647
Abstract
D. Garmann, A. Warnecke, F. Kratz and U. Jaehde
Extended Abstracts
Cerebrospinal fluid pharmacokinetics after different dosage regimens of intraventricular etoposide
C. Sirisangtragul, G. Henke, G. Fleischhack, S. Reif, C. Kloft, U. Bode and U. Jaehde
Price
42.00 $
Volume 41 p. 606 - 607
Abstract
C. Sirisangtragul, G. Henke, G. Fleischhack, S. Reif, C. Kloft, U. Bode and U. Jaehde
Extended Abstracts
Assessment of platinum sensitivity human tumor cells
J. Zisowsky, A. Becker, S. Weykam, M. Kassack and U. Jaehde
Price
42.00 $
Volume 41 p. 612 - 613
Abstract
J. Zisowsky, A. Becker, S. Weykam, M. Kassack and U. Jaehde
Pharmacodynamics
Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate
A. Becker, S. Vezmar, M. Linnebank, H. Pels, U. Bode, U. Schlegel and U. Jaehde
Price
42.00 $
Volume 45 p. 504 - 515
Abstract
A. Becker, S. Vezmar, M. Linnebank, H. Pels, U. Bode, U. Schlegel and U. Jaehde
1Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, 2Department of Neurology, University of Bonn, 3Department of Neurology, Ruhr-Universität Bochum, and 4Children’s Hospital, University of Bonn, Germany
Objective: Interference of methotrexate (MTX) with the metabolism of homocysteine may contribute to MTX neurotoxicity. In this pilot study we measured the concentration of homocysteine and related metabolites in the cerebrospinal fluid (CSF) of patients with primary central nervous system lymphoma undergoing intensive treatment with MTX. Material and methods: CSF samples from lymphoma patients (n = 4) were drawn at the end of high-dose MTX infusions (3 – 5 g/m2/24 h, HDMTX) and one day after intraventricular injections of MTX (3 mg, ICVMTX) or cytarabine (30 mg) and analyzed for homocysteine, cysteine, sulfur-containing excitatory amino acids (cysteine sulfinic acid, cysteic acid, homocysteine sulfinic acid and homocysteic acid), S-adenosylmethionine, 5-methyltetrahydrofolate and MTX. The concentration of homocysteine, cysteine and sulfur-containing excitatory amino acids were also measured in the CSF of a reference population not exposed to MTX. The Wilcoxon signed rank-test and the Friedman test were used to compare concentrations of homocysteine and its metabolites at various time-points during chemotherapy. Comparison of patient and control samples were performed using the Mann-Whitney U-test. Allelic variants of homocysteine metabolism previously shown to influence MTX neurotoxicity (MTHFR c.677C>T, MS c.2756A>G and Tc2 c.776C>G) were also analyzed. Results: After application of HD- and ICVMTX, the CSF homocysteine concentrations in the lymphoma patients were markedly elevated and significantly higher than those in the control group (p < 0.05, Mann-Whitney U-test), whereas 5-methyltetrahydrofolate was depleted. A rapid elevation of homocysteine sulfinic acid, a sulfur-containg amino acid which was not detected in the CSF of the control group, was observed. One patient developed confluent white matter brain changes visible using MRI. This patient had the lowest concentration of S-adenosylmethionine in the CSF and carried two risk alleles for MTX neurotoxicity. Conclusions: In this pilot study, MTX administered either intravenously or intraventricularly, induced marked biochemical alterations in the CSF. Whether these changes can be used to predict MTX-induced neurotoxicity at an early stage in treatment needs to be elucidated in larger clinical trials.Correspondence to:
Prof. Dr. U. Jaehde
Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany
Email: [email protected]
2008 CESAR: Annual Meeting – Extended Abstracts
Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin
I. Buß, G.V. Kalayda, P. Marques-Gallego, J. Reedijk and U. Jaehde
Price
42.00 $
Volume 47 p. 51 - 54
Abstract
I. Buß, G.V. Kalayda, P. Marques-Gallego, J. Reedijk and U. Jaehde
2008 CESAR: Annual Meeting – Extended Abstracts
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors
M.M. Henke, H. Richly, A. Drescher, M. Grubert, D. Alex, D. Thyssen, U. Jaehde, M.E. Scheulen and R.A. Hilger
Price
42.00 $
Volume 47 p. 58 - 60
Abstract
M.M. Henke, H. Richly, A. Drescher, M. Grubert, D. Alex, D. Thyssen, U. Jaehde, M.E. Scheulen and R.A. Hilger
Extended Abstract
Interindividual differences in oxaliplatin pharmacokinetics
A.M. Junker, A.C. Pieck, A. Wehmeier and U. Jaehde
Price
42.00 $
Volume 40 p. 569 - 570
Abstract
A.M. Junker1, A.C. Pieck2, A. Wehmeier1 and U. Jaehde2
Extended Abstract
Population pharmacokinetics of etoposide*
S. Reif, A. Jetter, U. Fuhr, H. McLeod, D. Kingreen, W. Siegert and U. Jaehde
Price
42.00 $
Volume 40 p. 578 - 579
Abstract
S. Reif1, A. Jetter2, U. Fuhr2, H. McLeod3, D. Kingreen4, W. Siegert4 and U. Jaehde1,5
Extended Abstract
Monitoring of methotrexate and reduced folates in the cerebrospinal fluid of cancer patients
S. Vezmar, U. Bode and U. Jaehde
Price
42.00 $
Volume 40 p. 582 - 583
Abstract
S. Vezmar1, U. Bode2 and U. Jaehde1
Extended Abstract
Population pharmacokinetics of cyclo- phosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy
S. Wilde, A. Jetter, M. Zaigler, S. Rietbrock, H. Menzel, M. Sieber, H. Tesch, G. Hempel, D. Busse, M. Schwab, S. Reif, U. Jaehde, V. Diehl and U. Fuhr
Price
42.00 $
Volume 40 p. 586 - 588
Abstract
S. Wilde1, A. Jetter1, M. Zaigler1, S. Rietbrock1, H. Menzel1, M. Sieber2, H. Tesch2, G. Hempel3, D. Busse4, M. Schwab4, S. Reif5, U. Jaehde5, V. Diehl2 and U. Fuhr1
Extended Abstract
Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells
M.L. Krieger, A. Konold, M. Wiese, U. Jaehde and G. Bendas
Price
42.00 $
Volume 48 p. 442 - 444
Abstract
Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells
M.L. Krieger, A. Konold, M. Wiese, U. Jaehde and G. Bendas
Extended Abstract
Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation
C. Mohn, G.V. Kalayda, H.-G. Häcker, M. Gütschow, S. Metzger and U. Jaehde
Price
42.00 $
Volume 48 p. 445 - 447
Abstract
Contribution of glutathione and MRP-mediated efflux to intracellular oxaliplatin accumulation
C. Mohn, G.V. Kalayda, H.-G. Häcker, M. Gütschow, S. Metzger and U. Jaehde
Extended Abstract
Intracellular ATP depletion leads to reduced platinum accumulation in ovarian cancer cells
V. Schneider, G.V. Kalayda, M.L. Krieger, G. Bendas and U. Jaehde
Price
42.00 $
Volume 48 p. 456 - 458
Abstract
Intracellular ATP depletion leads to reduced platinum accumulation in ovarian cancer cells
V. Schneider, G.V. Kalayda, M.L. Krieger, G. Bendas and U. Jaehde
Extended Abstracts
The 8th Annual Meeting of CESAR in St. Gallen – Novel therapeutic concepts in hemato-oncology
R. Morant, D. Sehrt and U. Jaehde
Volume 49 p. 58 - 59
Abstract
The 8th Annual Meeting of CESAR in St. Gallen – Novel therapeutic concepts in hemato-oncology
R. Morant, D. Sehrt and U. Jaehde
Extended Abstracts
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Volume 49 p. 88 - 90
Abstract
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Extended Abstracts
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
Volume 49 p. 96 - 98
Abstract
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
